$PODD

Bernstein Liebhard LLP said a shareholder filed a securities class action against Insulet Corp. (NASDAQ: PODD) for investors who bought shares between Feb. 21, 2025 and May 26, 2026. The suit alleges materially false or misleading statements and omissions about operations, growth prospects, and financial stability, leading to inflated prices and losses. Lead plaintiff papers due Aug. 31, 2026.

Pomerantz LLP said it filed a class action in Massachusetts federal court against Insulet Corp (NASDAQ: PODD) and certain officers. The suit covers purchases of Insulet securities from Feb 21, 2025 to May 26, 2026, alleging federal securities law violations. Insulet disclosed voluntary medical device corrections in March 2026 and May 2026, after which PODD shares fell $16.23 (6.88%) and $7.79 (5.07%).

Alpha Wealth Funds’ Q2 2026 “Insiders Fund” letter cited Insulet Corp (PODD) and said the fund fell 1.45% in June, up 8.43% in Q2, and 0.75% YTD versus S&P 500 -0.95%, 15.2%, 9.98%. PODD closed Aug 12 at $161.28, with -11.78% one-month and -54.06% 52-week returns. The letter referenced Omnipod 5 corrections tied to cannula tear risk and noted insider share purchases.

Insulet (PODD) reported Q2 2026 revenue of $801.7M, up 22.7% constant currency and above guidance. Adjusted EPS was $1.66, up 41.5%. U.S. Omnipod revenue was $544.1M, and international was $251.8M. Management revised U.S. full-year Omnipod growth to 17% to 19% and raised international to 30% to 32%, citing weaker type 2 retention.

Simply Wall St reports Insulet (PODD) shares fell 15% to about $141 after its latest quarterly results. Revenue was $802m in line with forecasts, while statutory profit was $1.37 per share. Analysts now expect 2026 revenue of $3.29b and EPS $6.17, with the consensus price target cut 27% to $172.

Insulet reported Q2 2026 results and said U.S. revenue guidance for 2026 was lowered to 20% to 22% growth due to lower-than-expected type 2 retention and utilization, especially in the first 90 days. The company is shifting sales incentives to prioritize retention, investing in Omnipod Discover, expanding customer care, and expects 2026 free cash flow to decline modestly.

US stock indices eased after early gains, with crude oil sliding to a 3-week low. WTI fell as reports said the US, Iran and Oman were nearing an interim Strait of Hormuz reopening deal, while Saudi Aramco said Houthi threats have not yet hit Red Sea crude exports. Bloomberg Intelligence projects Q2 earnings up about 23% and AI to drive much of S&P 500 EPS growth; markets price a 55% chance of a 25 bp Fed hike.

Insulet (NASDAQ:PODD) said execution issues hurt its U.S. Type 2 outlook and outlined steps to improve onboarding, customer support, retention-focused sales incentives, and use of Omnipod Discover. It raised 2026 guidance to 20% to 22% constant-currency total revenue growth and 21% to 23% Omnipod growth, with Q3 growth forecasts. Cash was $535M.

Insulet (NASDAQ:PODD) reported Q2 revenue of $801.7 million, up 23.5%, above guidance. Omnipod revenue rose 24.6%, with U.S. up 20.1% and international up 35.5%. It lowered full-year U.S. Omnipod growth to 17% to 19% from 20% to 22%, and total revenue to 20% to 22%. Adjusted EPS rose 41.5% to $1.66.

Oil prices fell after Axios said the US, Iran and Oman were nearing an interim deal to reopen the Strait of Hormuz. Houthi threats to escalate attacks on Saudi tankers and Trump’s comments added volatility. Bloomberg Intelligence expects Q2 earnings up about 23% and 86% of 387 S&P 500 firms beat estimates. Markets also priced rate-hike odds for the FOMC and ECB.